Developing a new medication can cost over $1 billion, depending on the drug’s complexity and expenses accrued via unsuccessful studies. Considering these costs, an optimized regulatory process is ...

SARASOTA, FL, July 18, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and ...

Program aims to support CMC development of products with expedited clinical development timeframes and provide patients with earlier access to these products Detalimogene has already been manufactured ...

As a part of this development strategy, Curanex will continue to advance its botanical drug development program in a stepwise ...

In this interview, News-Med talks to Tammy Newbold about the Global Harmonization of Regulatory CMC within Veterinary Medicine. Can you explain what global harmonization of regulatory CMC entails and ...

Safety and efficacy of two candidates are currently being assessed in investigator-initiated clinical trials. BRC is planning to commence enrollment for Phase 2 and 3 trials by mid 2026. MONTEREY, ...

Breakthrough Therapy designation based on interim clinical data from Phase I/II trials showing clinically meaningful improvements in cardiac biomarkers and functional measures LX2006 also selected for ...

As sponsors advanced more niche and personalized modalities, manufacturers were pushed to adopt holistic approaches to safety ...